Back to first-pass browser

First-pass extracted concept

SLC7A11/xCT

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

cystine/glutamate antiporter, SLC7A11, xCT

Extracted Explainers

What the tool is doing

SLC7A11/xCT is described as a cystine/glutamate antiporter that imports cystine to support glutathione biosynthesis and antioxidant defense. The review centers it as a key determinant of ferroptosis sensitivity and cancer metabolic state.

Source 1DOIPubMed

What problem it solves

In the review's framing, SLC7A11 helps cancer cells maintain antioxidant defense and suppress ferroptosis. This can support tumor growth in multiple human cancers.

Source 1DOIPubMed

What it does not solve

The abstract also states that SLC7A11 overexpression imposes metabolic costs, producing glucose and glutamine dependency rather than universally improving fitness.

Source 1DOIPubMed

Alternatives

The provided abstract does not name alternative transporters or substitute systems.

Source 1DOIPubMed

Evidence Snippets

The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1disease associationsupports2020Source 1DOIPubMed

SLC7A11/xCT is overexpressed in multiple human cancers.

Claim 2functional rolesupports2020Source 1DOIPubMed

SLC7A11/xCT imports cystine for glutathione biosynthesis and antioxidant defense.

Claim 3mechanistic rolesupports2020Source 1DOIPubMed

SLC7A11 overexpression promotes tumor growth partly by suppressing ferroptosis.

Claim 4metabolic dependencysupports2020Source 1DOIPubMed

High SLC7A11 expression is associated with metabolic reprogramming that leads to glucose and glutamine dependency in cancer cells.